Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Published:2023-11 Issue:11 Volume:10 Page:e890-e901
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Costa Luciano J,Chhabra Saurabh,Medvedova Eva,Dholaria Bhagirathbhai R,Schmidt Timothy M,Godby Kelly N,Silbermann Rebecca,Dhakal Binod,Bal Susan,Giri Smith,D'Souza Anita,Hall Aric C,Hardwick Pamela,Omel James,Cornell Robert F,Hari Parameswaran,Callander Natalie S

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma;Attal;N Engl J Med,2012

2. Lenalidomide after stem-cell transplantation for multiple myeloma;McCarthy;N Engl J Med,2012

3. Continuous lenalidomide treatment for newly diagnosed multiple myeloma;Palumbo;N Engl J Med,2012

4. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma;Facon;Blood,2018

5. Autologous transplantation and maintenance therapy in multiple myeloma;Palumbo;N Engl J Med,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How artificial intelligence revolutionizes the world of multiple myeloma;Frontiers in Hematology;2024-02-02

2. Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations;British Journal of Haematology;2024-01-30

3. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review;Blood Cancer Journal;2024-01-25

4. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience;Blood Cancer Journal;2024-01-10

5. Measurable Residual Disease and Decision-Making in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-01